Introduction {#Sec1}
============

Across the globe, \>1.46 billion adults \[[@CR1]\], and 170 million children \[[@CR2]\], are overweight or obese. It is well recognised that a woman's nutrition during pregnancy impacts pregnancy and birth outcomes, with the intra-uterine environment playing a key role in an individual's later health and disease \[[@CR3]\]. Maternal obesity significantly predicts child and adult obesity in her offspring \[[@CR4], [@CR5]\], and associated cardio-metabolic risk factors, including hypertension, hyperlipidaemia, diabetes, and cardiovascular disease \[[@CR6]--[@CR8]\]. Kitsantas and colleagues \[[@CR9]\] report that maternal pre-gravid obesity increases the odds of pre-school obesity by a factor of 1.6 (OR 1.60; 95% CI 1.26--2.03), while Rooney and colleagues \[[@CR10]\] report a substantially greater increase in risk (RR 6.35; 95% CI 3.28--12.30). Exposure to such an intra-uterine environment potentially creates a vicious cycle in which the propensity to obesity is perpetuated, with major adverse public health implications \[[@CR11], [@CR12]\], and implications for the health of successive generations \[[@CR13]\].

There has been considerable research interest in the provision of antenatal dietary interventions during pregnancy to limit weight gain and improve pregnancy and birth outcomes for women and their infants. A comprehensive systematic review by Thangaratinam and colleagues \[[@CR14]\] has identified numerous studies assessing dietary and lifestyle interventions in pregnancy, albeit mostly small in scope. While the findings reveal a relatively modest impact on weight gain \[[@CR14]\], very little attention has been directed towards the ongoing follow-up of women and infants beyond the neonatal period to assess longer term outcomes.

To our knowledge, only three randomised trials involving the provision of an antenatal dietary intervention \[[@CR15]--[@CR17]\] have conducted and reported findings of follow-up to 6 months after birth \[[@CR18]--[@CR20]\]. However, these studies have been limited by the relatively low rates of assessment \[[@CR18]--[@CR20]\]. Furthermore, studies have focussed predominantly on measures of adiposity, and have not reported other clinically relevant infant outcomes \[[@CR18], [@CR20]\], or specifically reported infant outcomes among women who are overweight or obese \[[@CR19]\].

We have previously shown that a comprehensive dietary and lifestyle intervention during pregnancy, in women who are overweight or obese, significantly improves both maternal diet and physical activity \[[@CR21]\], is associated with an 18 and 41% relative reduction in the risk of high infant birth weight above 4 and 4.5 kg \[[@CR22], [@CR23]\], and was a cost neutral intervention \[[@CR24]\]. On-going participant follow-up is required to assess the further impact of these findings on childhood outcomes. This manuscript reports the effect of the LIMIT antenatal dietary intervention, on 6-month infant outcomes.

Methods {#Sec2}
=======

The methods and primary clinical findings of the LIMIT randomised trial have been published \[[@CR21]--[@CR23]\], with the trial registered on the Australian and New Zealand Clinical Trials Registry (ACTRN12607000161426). Briefly, we conducted a multicentre randomised trial involving women with a singleton pregnancy, between 10^+0^ and 20^+0^ weeks' gestation, and body mass index ≥25.0 kg/m^2^, who were randomised to either an antenatal dietary and lifestyle intervention (Lifestyle Advice Group) or standard antenatal care (Standard Care Group) \[[@CR22]\].

Women in the Lifestyle Advice group received a comprehensive intervention over the course of their pregnancy that included a combination of dietary, exercise and behavioural strategies, delivered by a research dietician and trained research assistants \[[@CR22]\]. Dietary information was consistent with current Australian standards \[[@CR25]\], while physical activity advice focussed on the benefits of exercise in pregnancy \[[@CR26]\]. Women were encouraged to set achievable goals for change, supported to make these lifestyle changes, to identify potential barriers and enablers to their implementation, and to self-monitor their progress \[[@CR21], [@CR22]\]. This information was delivered through two dedicated sessions with the research dietician (at trial entry, and 28 weeks) and trained research assistants (via telephone call at 22, 24, and 32 weeks, and a face--face visit at 36 weeks) \[[@CR21], [@CR22]\].

Study design {#Sec3}
------------

We conducted follow-up of infants born to women who participated in the LIMIT randomised trial 6-months after birth.

Participants {#Sec4}
------------

Women who participated in the LIMIT randomised trial, gave birth to a live infant, and who provided consent to the ongoing follow-up of their child, were eligible for inclusion. Women who suffered a stillbirth or neonatal death, or who withdrew from participation in ongoing follow-up were excluded.

Follow-up schedule {#Sec5}
------------------

Each infant was assessed by a research assistant, blinded to the allocated treatment group. Eligible women were contacted to arrange a follow-up assessment of their child, either at the hospital of their birth, or if more convenient, for a research assistant to visit their home.

Primary outcome {#Sec6}
---------------

The primary outcome was the incidence of infant BMI z-score ≥90th centile for infant age and sex at follow-up \[[@CR27]\].

Secondary outcomes {#Sec7}
------------------

Infant Anthropometric Measurements: We have an established and validated method of conducting anthropometric measurements in infants \[[@CR28]\]. Information obtained included the infant's length, weight, weight-for-length, and anthropometric measurements (arm, thigh, waist and hip circumferences; biceps, triceps, sub-scapular, abdominal, supra-iliac and thigh skin-fold thickness). Research assistants used Harpenden skin-fold callipers to obtain skinfold thickness measurements, and received ongoing standardised training \[[@CR29]\]. Weight, length, BMI, weight-for-length, and head circumference measures were converted to z-scores for age and gender, using WHO standards \[[@CR27], [@CR30]\].

Infant Neurodevelopment: The infant's primary caregiver was asked to complete a structured Ages and Stages Questionnaire (ASQ) \[[@CR31]\], reporting five domains of development (communication, gross motor, fine motor, problem solving, and personal-social skills). Possible responses included Yes, Sometimes, or No, with a score in any one domain \>2SD below the mean considered indicative of the need for further assessment and when identified, the primary caregiver was advised to seek additional medical advice. The ASQ has been validated against the Bayley Scales \[[@CR32]\], and in a paediatric population \[[@CR33]\].

General health, health service utilisation, and quality of life: as assessed by questionnaire \[[@CR34]\] completed by the infant's primary caregiver.

Infant Feeding: (breast, formula, or a combination of the two), as assessed by questionnaire completed by the infant's primary caregiver.

Sample size {#Sec12}
-----------

The available sample size for follow-up assessment at 6-months of age was predetermined by the LIMIT trial, which was powered on the primary outcome of large for gestational age, with 2212 women randomised \[[@CR22]\]. Using data from the general Australian population, we anticipated a minimum incidence in the standard care group of BMI z-score ≥90th centile of approximately 25% \[[@CR35]\]. A sample size of 1350 infants (75% follow-up) would provide 80% power to detect at least a difference in the incidence of BMI z-score ≥90th centile of 6.4% (from 25 to 18.6%; alpha 0.05). Detectable differences would range from 6.2% (with follow-up of 80% of children), to 6.7% (with follow-up of 70% of children; alpha 0.05; power 80%). Small but relevant differences of 0.15--0.16 standard deviations in secondary continuous outcomes could also be detected.

Statistical analysis {#Sec13}
--------------------

The analysis was conducted using intention to treat principles, according to the treatment group the woman was randomised to in pregnancy (Lifestyle Advice or Standard Care). Missing data were imputed for all randomised participants except those who had no live birth, who had an infant death, or who withdrew from the study and also withdrew permission to use data. Data were imputed separately by treatment group using the fully conditional specification (chained equations) method to create 100 complete datasets for analysis under the assumption that the data were missing at random (i.e., that "missingness" was independent of the values of the missing observations, conditional on observed data). In order to make the MAR assumption more plausible, a range of auxiliary variables, including stratification (centre, parity, BMI category) and adjustment variables (socioeconomic status, smoking, maternal age at consent, infant gender), along with infant birth measures (weight, length, circumferences and skinfold thickness measures), were included in the imputation model. The results of imputed analyses were compared with those from complete-case analyses, and further sensitivity analyses were also conducted for the primary outcome on the assumption that data were Missing Not At Random (MNAR). That is, analyses were conducted assuming that missing values had, firstly, a substantially greater incidence, and secondly, a substantially reduced incidence of z-scores \>90th percentile as compared with the observed data.

Both adjusted and unadjusted analyses were performed, with adjustment for variables used to stratify randomisation (maternal early pregnancy BMI category, parity, and centre of birth), in addition to maternal socioeconomic status, age, and smoking status. Infant outcomes other than z-scores were additionally adjusted for gender and actual age at assessment. For binary outcomes, relative risks with 95% CI were estimated using log binomial regression. For continuous outcomes, differences in means with 95% CI were estimated using linear regression. Analyses were performed to test for effect modification by maternal BMI category. Statistical significance was set at *p* \< 0.05 (two-sided) with no adjustment for multiple comparisons, and all analyses followed a pre-specified plan.

Ethics {#Sec14}
------

Approval was granted by the Women's and Children's Local Health Network Human Research and Ethics Committee at the Women's and Children's Hospital, the Central Northern Adelaide Health Service Ethics of Human Research Committee (Lyell McEwin Hospital) and the Flinders Clinical Research Ethics Committee (Flinders Medical Centre). All participants provided written informed consent to participate.

Results {#Sec15}
=======

Figure [1](#Fig1){ref-type="fig"} outlines the flow of participants. A total of 2136 infants were eligible for the follow-up study and included in the analysis (96.6% of the randomised sample). There were 1754 infants who were assessed at 6 months of age (Lifestyle Advice *n* = 869; Standard Care *n* = 885), representing 82.1% of the eligible sample. There were five deaths to 6 months of age (4 neonatal deaths as reported previously \[[@CR22]\], and the death of one infant prior to 6 months of age attributable to sudden infant death syndrome). Table [1](#Tab1){ref-type="table"} describes the baseline characteristics of the subset of eligible maternal participants, and are similar to the entire randomised cohort (data not shown) \[[@CR22]\]. The median BMI of the cohort was 31.0 kg/m^2^ (Inter Quartile Range (IQR) 27.8--35.6 kg/m^2^), with 42.1% of women overweight, and 57.9% obese.Fig. 1Flow of participantsTable 1Baseline characteristics for 6 month participantsCharacteristicLifestyle advice (*N* = 1071)Standard care (*N* = 1065)Total (*N* = 2136^e^)Maternal Age (Years)^a^29.6 (5.4)29.8 (5.3)29.7 (5.4)Gestational Age at Entry (Weeks)^b^14.3 (12.0--17.0)14.3 (12.1--17.1)14.3 (12.0--17.4)Body Mass Index (kg/m^2^)^b^31.2 (28.0--35.8)31.0 (27.7--35.4)31.0 (27.8--35.6)Body Mass Index Category^c^ BMI 25.0--29.9358 (41.2)381 (43.1)739 (42.1) BMI 30.0--34.9226 (30.2)256 (28.9)518 (29.5) BMI 35.0--39.9159 (18.3)148 (16.7)307 (17.5) BMI \> = 40.090 (10.4)100 (11.3)190 (10.8)Weight (kg)^a^88.3 (16.6)88·0 (17.6)88.1 (17.1)Height (cm)^a^164.9 (6.4)164·7 (6.5)164.8 (6.5)Race^c^ Caucasian790 (90.9)802 (90.6)1592 (90.8) Asian19 (2.2)31 (3.5)50 (2.9) Indian35 (4.0)30 (3.4)65 (3.7) Other25 (2.9)22 (2.5)47 (2.7)Smoker^c^98 (11.3)91 (10.3)189 (10.8)Nulliparous^c^359 (41.3)353 (39.9)712 (40.6)Index of Socio-economic Disadvantage^d^ Unknown1 (0.1)1 (0.1)2 (0.1) Quintile 1 (Most Disadvantaged)256 (29.5)251 (28.4)507 (28.9) Quintile 2214 (24.6)222 (25.1)436 (24.9) Quintile 3139 (16.0)134 (15.1)273 (15.6) Quintile 4122 (14.0)141 (15.9)263 (15.0) Quintile 5 (Least Disadvantaged)137 (15.7)136 (15.4)273 (15.6)^a^mean and standard deviation^b^median and interquartile range^c^number and %^d^Socioeconomic index as measured by SEIFA IRSD^e^Includes all women whose infants were eligible for the 6 month follow-up study

There were no statistically significant differences in the incidence of infant BMI z-score ≥90th centile for infants born to women in the Lifestyle Advice group, as compared with those born to women in the Standard Care group (Lifestyle Advice 233 (21.71%) vs. Standard Care 233 (21.90%); adjusted relative risk aRR 0.99; 95% confidence interval (CI) 0.82 to 1.18; *p* = 0.88), or in infant BMI z-score ≥85th centile (Lifestyle Advice 299 (27.88%) vs. Standard Care 303 (28.48%); aRR 0.97; 95% confidence interval (CI) 0.84 to 1.13; *p* = 0.71) (Table [2](#Tab2){ref-type="table"}). Infants were not statistically significantly different between the two treatment groups with regards their weight (Lifestyle Advice 8.26 kg (±1.33) vs. Standard Care 8.29 kg (±1.33); adjusted mean difference (aMD) −0.05; 95% CI −0.16 to 0.06; *p* = 0.38), weight Z-score (Lifestyle Advice 0.30 (±1.13) vs. Standard Care 0.34 (±1.11); aMD −0.04; 95% CI −0.14 to 0.06; *p* = 0.43), length (Lifestyle Advice 68.24 cm (±3.76) vs. Standard Care 68.28 cm (±4.13); aMD −0.12; 95% CI −0.41 to 0.16; *p* = 0.41), length Z-score (Lifestyle Advice 0.06 (±1.22) vs. Standard Care 0.11 (±1.28); aMD −0.04; 95% CI −0.16 to 0.07; *p* = 0.46), weight for length ratio (Lifestyle Advice 0.12 (±0.01) vs. Standard Care 0.12 (±0.01); aMD −0.00; 95% CI −0.00 to 0.00; *p* = 0.72), or weight for length ratio Z-score (Lifestyle Advice 0.44 (±1.18) vs. Standard Care 0.48 (±1.14); aMD −0.04; 95% CI −0.15 to 0.07; *p* = 0.47). Body circumference and skin-fold thickness measures also did not differ significantly between infants born to women who received the antenatal intervention, and those who received standard care.Table 26 month infant weight and anthropometric outcomes by treatment groupOutcomeLifestyle advice (*N* = 1071)Standard Care (*N* = 1065)Unadjusted treatment effect (95% CI)Unadjusted *P*-valueAdjusted treatment effect (95% CI)Adjusted *P*-valueBMI z-score ≥90th centile\*233 (21.71)233 (21.90)0.99 (0.83, 1.19)0.9270.99 (0.82, 1.18)0.882BMI z-score ≥85th centile\*299 (27.88)303 (28.48)0.98 (0.84, 1.14)0.7830.97 (0.84, 1.13)0.713BMI17.68 (1.82)17.70 (1.79)−0.01 (−0.18, 0.16)0.873−0.02 (−0.19, 0.15)0.824BMI z-score0.37 (1.17)0.38 (1.16)−0.01 (−0.12, 0.10)0.860−0.01 (−0.12, 0.09)0.792Weight (kg)8.26 (1.33)8.29 (1.33)−0.03 (−0.15, 0.09)0.619−0.05 (−0.16, 0.06)0.376Weight z-score0.30 (1.13)0.34 (1.11)−0.04 (−0.14, 0.06)0.453−0.04 (−0.14, 0.06)0.426Length (cm)68.24 (3.76)68.28 (4.13)−0.05 (−0.41, 0.31)0.793−0.12 (−0.41, 0.16)0.407Length z-score0.06 (1.22)0.11 (1.28)−0.05 (−0.16, 0.07)0.444−0.04 (−0.16, 0.07)0.463Weight-Length Ratio0.12 (0.01)0.12 (0.01)−0.00 (−0.00, 0.00)0.881−0.00 (−0.00, 0.00)0.718Weight-Length Ratio z-score0.44 (1.18)0.48 (1.14)−0.03 (−0.14, 0.07)0.525−0.04 (−0.15, 0.07)0.466Head circumference (cm)43.83 (1.77)43.79 (1.88)0.04 (−0.13, 0.21)0.6550.03 (−0.12, 0.18)0.698Head circumference z-score0.45 (1.08)0.43 (1.13)0.02 (−0.08, 0.12)0.6840.03 (−0.08, 0.13)0.602Chest circumference (cm)44.45 (2.77)44.51 (2.75)−0.06 (−0.33, 0.21)0.677−0.09 (−0.35, 0.17)0.485Abdominal circumference (cm)44.53 (3.79)44.35 (3.76)0.18 (−0.19, 0.55)0.3460.16 (−0.20, 0.52)0.392Arm circumference (cm)14.97 (1.31)14.95 (1.34)0.02 (−0.11, 0.15)0.7760.01 (−0.11, 0.14)0.841Biceps SFTM (mm)6.47 (2.00)6.34 (2.00)0.13 (−0.09, 0.35)0.2570.12 (−0.10, 0.34)0.275Triceps SFTM (mm)10.03 (2.53)10.24 (2.52)−0.21 (−0.49, 0.06)0.129−0.22 (−0.50, 0.06)0.120Subscapular SFTM (mm)6.94 (1.81)6.93 (1.87)0.02 (−0.18, 0.22)0.8810.01 (−0.19, 0.21)0.936Supra-iliac SFTM (mm)11.50 (4.91)11.34 (5.13)0.16 (−0.37, 0.69)0.5470.14 (−0.38, 0.66)0.600Abdominal SFTM (mm)7.81 (2.39)7.89 (2.39)−0.08 (−0.33, 0.17)0.543−0.09 (−0.33, 0.16)0.492Thigh SFTM (mm)18.43 (4.58)18.32 (4.17)0.11 (−0.37, 0.59)0.6420.08 (−0.39, 0.56)0.725Sum of SFTM (mm)60.79 (12.61)60.50 (12.68)0.30 (−0.96, 1.56)0.6440.25 (−1.01, 1.50)0.703Values for continuous outcomes are mean and standard deviation and treatment effects are differences in means. Values for binary outcomes (\*) are number and percentage and treatment effects are relative risks. All estimates are based on imputed data including all infants who were eligible for the follow-up study.Adjusted analyses included the stratification variables BMI category, parity and centre, as well as maternal age, socioeconomic status and maternal smoking. Non z-score outcomes were additionally adjusted for actual age at assessment and infant gender.

There were no statistically significant differences identified between infants born to women in the Lifestyle Advice group and those in the Standard Care group with regards to the overall Ages and Stages total score (Lifestyle Advice 262.47 (±34.92) vs. Standard Care 258.72 (±36.54); aMD 3.53; 95% CI −0.33 to 7.40; *p* = 0.07), or in the proportion of infants identified with \>1 domain below the cut-off (Lifestyle Advice 49 (4.58%) vs. Standard Care 69 (6.51%); aRR 0.69; 95% CI 0.43 to 1.11; *p* = 0.13) (Table [3](#Tab3){ref-type="table"}). Similarly, there were no statistically significant differences between the two groups with regards to the individual components of the Ages and Stages score (Table [3](#Tab3){ref-type="table"}).Table 36 month infant neurodevelopmental outcomes by treatment group, assessed by the Ages and Stages QuestionnaireOutcomeLifestyle advice (*N* = 1071)Standard care (*N* = 1065)Unadjusted treatment effect (95% CI)Unadjusted *P*-valueAdjusted treatment effect (95% CI)Adjusted *P*-valueCommunication domain51.30 (9.03)50.95 (9.63)0.35 (−0.68, 1.38)0.5010.36 (−0.67, 1.38)0.493Gross motor domain53.35 (10.05)52.74 (10.84)0.61 (−0.54, 1.75)0.2970.55 (−0.59, 1.69)0.344Fine motor domain52.25 (10.52)51.20 (10.74)1.05 (−0.11, 2.21)0.0751.00 (−0.13, 2.14)0.082Problem solving domain53.60 (9.55)52.86 (9.15)0.74 (−0.29, 1.76)0.1580.72 (−0.31, 1.74)0.170Social domain51.71 (9.52)50.95 (9.74)0.77 (−0.34, 1.87)0.1730.69 (−0.41, 1.79)0.218Total score262.47 (34.92)258.72 (36.54)3.75 (−0.13, 7.63)0.0583.53 (−0.33, 7.40)0.073More than 1 score below cut-off^\*^49 (4.58)69 (6.51)0.70 (0.44, 1.12)0.1370.69 (0.43, 1.11)0.126Values are mean and standard deviation (or number and percentage), and treatment effects are differences in means (or relative risks) and are based on imputed data including all infants who were eligible for the follow-up studyAdjusted analyses included the stratification variables BMI category, parity and centre. Outcomes were additionally adjusted for maternal age, socioeconomic status and maternal smoking

There were no significant differences between the two treatment groups with regards to infant feeding patterns, with 59.80% of infants still being breast fed at 6 months of age (Lifestyle Advice 324 (59.12%) vs. Standard Care 347 (60.45%); aRR 1.01; 95% CI 0.97 to 1.05; *p* = 0.60). Similarly, there were no significant differences identified with regards to general health or health service utilisation (Table [4](#Tab4){ref-type="table"}).Table 46 month infant general health and health utilisation outcomes by treatment groupOutcomeLifestyle Advice (N = 1071)Standard Care (*N* = 1065)Unadjusted Treatment Effect (95% CI)Unadjusted *P*-valueAdjusted Treatment Effect (95% CI)Adjusted *P*-valueWell Since Discharge491 (83.50)548 (87.82)0.95 (0.91, 1.00)0.0330.96 (0.92, 1.01)0.131Visited Doctor/Hospital Since Discharge251 (42.83)267 (42.86)1.00 (0.88, 1.14)0.9930.97 (0.85, 1.11)0.690Admitted to Hospital36 (14.34)33 (12.36)1.16 (0.75, 1.80)0.5071.08 (0.68, 1.71)0.740Values are number and percentage, and treatment effects are relative risks based on imputed data including all infants who were eligible for the follow-up studyAdjusted analyses included the stratification variables BMI category, parity and centre. Outcomes were additionally adjusted for maternal age, socioeconomic status and maternal smoking

There was no evidence to suggest that the effect of the antenatal intervention was modified by maternal BMI category for any of the reported outcomes (data not shown). In addition, results were compared to those of analyses using unimputed data, and (for the primary outcome) to the results of sensitivity analyses using data imputed under various MNAR assumptions. The results, in terms of both direction and magnitude of effect, were consistent across all of these analyses.

Discussion {#Sec16}
==========

Our findings indicate that provision of an antenatal dietary intervention for overweight or obese women was not associated with effects on infant growth, measures of adiposity, and neurodevelopmental outcomes at 6 months of age. There was no evidence to suggest that the effects of the intervention were modified by maternal BMI category.

Our findings represent the largest, most extensive, and most complete follow-up of infants to 6 months of age who were born to overweight and obese women following the conduct of the largest randomised trial to date evaluating the provision of a comprehensive antenatal dietary and lifestyle intervention. We have utilised robust methodology in terms of obtaining accurate measurement of early pregnancy weight, height, and BMI; detailed maternal dietary and physical activity history; and have delivered the antenatal intervention in a consistent manner to participants. Furthermore, we have utilised robust methodology to obtain anthropometric measures of the infants at 6 months of age, adhering to a standardised, research quality protocol.

A number of techniques have been described in the assessment of early infant body composition. Measurement of infant skinfold thickness \[[@CR36], [@CR37]\] and bio-impedance are considered reliable and relatively non-invasive methods of assessing fat distribution, both of which have been correlated with more invasive measures \[[@CR36], [@CR38]--[@CR40]\]. Furthermore, percentage fat, as determined by skinfold thickness measurements has been validated against DXA calculations of fat mass in both infants and children \[[@CR36], [@CR41]\]. Although these more detailed body composition assessment tools may have yielded more accurate estimates of the relative proportions of adipose and lean tissue mass, they were not considered feasible for use in the large scale setting required for this follow-up study, and its associated practical and financial constraints.

Similarly, the use of the Ages and Stages questionnaire is considered a screening tool to identify infants at risk of neurodevelopmental delay \[[@CR31]\]. While the use of a more sensitive test would provide more detailed and accurate estimates of early neurodevelopmental achievement, the ASQ has been validated against robust assessment tools \[[@CR32]\], and in a paediatric population \[[@CR33]\]. Again, the resources and intensive psychology training required to administer, for example, the more complex Bayley Scale, while generating more detailed information, was not considered feasible in our study population.

A potential limitation of our follow-up study is the risk of selection bias, with only 82% of the available cohort contributing data at 6-month follow-up assessments. We consider this risk, and the impact on the validity of our findings to be low. Characteristics of the women and infants for whom data was available and who participated in the 6-month follow-up study were similar between the two randomised treatment groups, and similar to the full randomised cohort \[[@CR22]\]. Further, analyses were based on all infants who were eligible for follow-up (96.6% of those randomised) by using multiple imputation to address missing data for infants who were not assessed at 6 months.

Our findings indicate no evidence of an effect of a comprehensive dietary and lifestyle intervention provided during pregnancy for women who are overweight or obese, on measures of infant growth, adiposity, and neurodevelopment at 6-months of age. This is despite our previously published findings of significant but modest improvements in maternal diet and physical activity during pregnancy \[[@CR21]\], and an 18 and 41% relative reduction in risk of infant birth weight above 4 \[[@CR22]\] and 4.5 kg, respectively \[[@CR23]\]. While this may reflect evidence of a true lack of persisting effect of maternal dietary modification and birth weight on weight at 6-months of age, it may also be indicative that other factors are of relatively greater importance in driving early, ex-utero, infant growth and development.

Previous evidence on the longer-term effects of antenatal dietary and lifestyle interventions is limited. Vinter and colleagues \[[@CR18]\] conducted a follow-up assessment of participants 6-months after birth, in which an antenatal dietary and lifestyle intervention was provided to overweight and obese women \[[@CR15]\]. Although an assessment was conducted at 6 months post-partum involving 66% of participants \[[@CR18]\], there have been no early infant outcomes reported to date. Follow-up of a smaller proportion of child participants at 2 to 3 years of age \[[@CR42], [@CR43]\] demonstrated no significant differences in the metabolic profile of children \[[@CR42]\], or on measures of growth and adiposity \[[@CR43]\].

The ROLO trial evaluated the effect of a low glycaemic index diet among women who had previously given birth to an infant with weight above 4 kg \[[@CR16]\]. While not all women who participated in this trial were overweight or obese (mean BMI 26.8 kg/m^2^), there was no evidence of an effect on infant birth weight \[[@CR16]\]. Furthermore, follow-up of 280 infants (35% of the randomised cohort) at 6-months of age demonstrated no evidence of an effect of the intervention on early infant measures of growth or adiposity \[[@CR19]\].

The UPBEAT trial evaluated the effect of an antenatal dietary and lifestyle intervention among obese women, with no impact on infant birth weight demonstrated \[[@CR17]\]. However, recently published findings from approximately 46% of eligible infants at 6 months of age (698 of 1522 eligible infants assessed) suggest a very small reduction in subscapular skinfold thickness measurement of \~0.4 mm following provision of the antenatal intervention \[[@CR20]\]. While statistically significant, the clinical significance of such a small difference is questionable, the findings also consistent with a chance occurrence, particularly as this was a secondary outcome, and no other statistically significant differences were identified between the treatment groups in infant BMI, abdominal circumference, or the remainder of infant anthropometric measures obtained.

There is emerging evidence, both from animal and human studies, of an association between maternal obesity and significantly higher risks of impaired offspring cognitive, motor and behavioural aspects of neurodevelopment \[[@CR44]--[@CR46]\]. Children born to women who are overweight or obese are more likely to be identified with moderate to severe cognitive, motor and global developmental delay at 3 years of age \[[@CR46]\], as well as poorer academic achievement extending to 14 years of age \[[@CR44], [@CR45]\]. Autism spectrum disorders in childhood have also been observed and diagnosed more frequently among children born to women with metabolic conditions identified during pregnancy, including diabetes and obesity \[[@CR47]\]. Our findings report, for the first time, the impact of an antenatal dietary intervention for women who are overweight or obese on early infant neurodevelopment. While we did not identify statistically or clinically significant differences in neurodevelopment at 6-months of age using a reliable screening tool, ongoing follow-up of participants further into childhood will again be important to determine whether there are any potential benefits of improving maternal diet and physical activity during pregnancy on childhood neurodevelopment.

Conclusions {#Sec17}
===========

Antenatal dietary and lifestyle advice did not alter infant growth and adiposity at 6-months of age. Despite this, it remains important to continue to follow-up the children whose mothers participated in this intervention trial, particularly in view of the well recognised association between high-infant birth weight and subsequent childhood obesity \[[@CR48]\], and the emerging associations between maternal obesity and impaired childhood neurodevelopmental function \[[@CR46]\]. It will be valuable to utilise our clinical and biological databases to explore potential pathways whereby maternal obesity contributes to childhood outcomes, including obesity and impaired neurodevelopment.
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